News for Werewolf Therapeutics, Inc. (HOWL)

WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the ”œCompany” or ”œWerewolf”) ( HOWL), an innovative biopharmaceutical

**media[652934]**

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the ”œCompany” or ”œWerewolf”) ( HOWL), an innovative biopharmaceutical

Bank of America has revised its price target for Werewolf Therapeutics (HOWL), reducing it from $10 to $9, while maintaining a Buy rating on the stock. Despite

Wedbush has revised its price target for Werewolf Therapeutics (HOWL), reducing it from $8 to $6. This adjustment reflects a shift in expectations for future fi

- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a mor

Werewolf Therapeutics (HOWL) recently unveiled new data on its WTX-921 molecule at IMMUNOLOGY2025, hosted by the American Association of Immunologists in Honolu

WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the â\u0080\u009cCompanyâ\u0080\u009d or â\u0080\u009cWerewolfâ\u0080\u009d) ( HOWL), an innovative biopharmaceutical

**media[614514]**

WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the ”œCompany” or ”œWerewolf”) ( HOWL), an innovative biopharmaceutica

”“ Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizum

WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the ”œCompany” or ”œWerewolf”) ( HOWL), an innovative biopharmaceutica

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. ( HOWL), an innovative biopharmaceutical company pioneering the development of

**media[548365]**

Overview of the Recent Transaction On December 31, 2024, PFM Health Sciences, LP (Trades, Portfolio) executed a significant transaction involving Werewolf Thera

”“ Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on pot

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the ”œCompany” or ”œWerewolf”) ( HOWL), an innovative biopharmaceutical

Werewolf Therapeutics beats Q3 earnings expectations with a GAAP EPS of -$0.38.